IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to ...

Fast Company recognizes 609 organizations across 58 sectors and regions. IO Biotech has been recognized for its potentially game-changing approach to immune-mod • Findings support the ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company’s prestigious list of the World’s Most ...

IO Biotech, a clinical-stage biopharmaceutical company with a global footprint, is developing novel, immune-modulating cancer therapies designed to activate naturally occurring T cells that target ...

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq ...

IO Biotech, a Danish med-tech company, has obtained €57.5 million in venture debt financing from the European Investment Bank, with backing fro ...

IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The ...

BAKU, Azerbaijan, March 28. Danish med-tech company IO Biotech has secured a 57.5 million euro venture debt agreement with the European Investment Bank (EIB), Trend reports. The deal consists of ...

IO Biotech has a 52-week low of $0.66 and a 52-week high of $1.85. Institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in shares of IO ...